Novo Nordisk Slashes US List Prices Of Several Insulin Products By Up To 75%

RTTNews | hace 788
Stocktwits
Novo Nordisk Slashes US List Prices Of Several Insulin Products By Up To 75%

(RTTNews) - Healthcare company Novo Nordisk Inc. (NVO) announced Tuesday it is lowering the U.S. list prices of several pre-filled insulin pens and vials by up to 75% for people living with type 1 and type 2 diabetes.

The products include both pre-filled pens and vials of basal (long-acting), bolus (short-acting) and pre-mix insulins, specifically Levemir, Novolin, NovoLog and NovoLog Mix 70/30.

Novo Nordisk is also reducing the list price of unbranded biologics to match the lowered price of each respective branded insulin. These changes will go into effect on January 1, 2024.

Novo Nordisk currently provides co-pay support for a number of insulin products, meaning eligible patients can pay $25 to $35 for their insulin.

Novo Nordisk recognizes that some patients find it difficult to pay for healthcare, including insulin. As such, the Company remains committed to reducing the burden of out-of-pocket costs, helping transform the complex pricing system, and fostering better pricing predictability.

Novo Nordisk continually reviews and revises its offerings as well as works with diverse stakeholders to create solutions for differing patient needs.

Tags: NVO
Stocktwits
read more
Novo Nordisk Stock Climbs On Higher Q1 Results; Cuts FY25 Outlook

Novo Nordisk Stock Climbs On Higher Q1 Results; Cuts FY25 Outlook

Shares of Novo Nordisk A/S were gaining around 6 percent in Denmark as well as around 7 percent in the pre-market activity on the NYSE, after the Danish drug major reported Wednesday higher profit and sales in its first quarter, mainly reflecting improved results of its blockbuster weight loss drug Wegovy. Meanwhile, the company trimmed fiscal 2025 outlook for sales and operating profit growth...
RTTNews | hace 3
Novo Nordisk Plans $4.1 Bln NC Facility To Boost Obesity Drug Supply

Novo Nordisk Plans $4.1 Bln NC Facility To Boost Obesity Drug Supply

Danish drug maker Novo Nordisk announced its plans to invest $4.1 billion or about 27 billion Danish kroner to build a new manufacturing plant in Clayton, North Carolina with a view to expanding its manufacturing capacity in the United States. In the new plant, the company plans to produce current and future injectable treatments for people with obesity and other serious chronic diseases.
RTTNews | hace 320
U.S. Dollar Declines On Trade Deal Optimism

U.S. Dollar Declines On Trade Deal Optimism

The U.S. dollar weakened against its major counterparts in the New York session on Friday as investors looked ahead to discussions between the U.S. and China scheduled for this weekend.
RTTNews | hace 1
Swiss Market Ends On Positive Note

Swiss Market Ends On Positive Note

The Swiss market closed higher on Friday as easing concerns about trade tensions following the announcement of a trade deal between the U.S. and U.K., and upcoming talks between U.S. and China helped keep the mood positive.
RTTNews | hace 1
TSX Modestly Higher On Positive Jobs Data, Earnings Updates

TSX Modestly Higher On Positive Jobs Data, Earnings Updates

The Canadian market is modestly higher around noon on Friday, riding on gains in communications, energy and materials sectors. Optimism about the U.S. and China agreeing on a trade deal this weekend, close on the heels of U.S. President Donald Trump unveiling the framework of a trade agreemen
RTTNews | hace 1
Herramientas
Calendario económico
Market Hours
Interest Rates
Holidays Calendar
Mercados Forex
Volatilidad Forex
Correlación Forex
Noticias del Forex
forex analysis
Datos COT
Liquidez
Calculadoras Forex
Heat Map del Forex
Indicators Heatmap
Comunidad
Comunidad
Sistemas
Sistemas más populares
Estrategias
Concursos
Gráficos Forex
Sentimiento Forex
Indicador de perspectivas
Revisiones
Corredores de bolsa
Prop Trading Firms
Servicios SPV
Proveedor de señales
Servicios de programación de AE
Affiliate Programs
Servicios de corretaje PAMM
Servicios de programas de rebaja
Plataformas de trading
Asesores Expertos
Exchanges de Criptomonedas
Trading Courses
Corredores de bolsa
Spreads de Forex
Cotizaciones de los corredores de Forex
Swaps de corredores de Forex
Volumen del corredor Forex
Promociones de corredores Forex Press Release
Plataforma
Widgets
Funciones
API
RSS
Stock Portfolio
Affiliate Software
Gráficos avanzados
Soporte
FAQ
Ayuda
Póngase en contacto con nosotros
¡Informar de un error!
Acerca de
Blog
© 2025 Myfxbook Ltd. Todos los Derechos Reservados.
ADVERTENCIA DE ALTO RIESGO: El comercio de divisas implica un alto nivel de riesgo que puede no ser adecuado para todos los inversores. El efecto de apalancamiento crea un riesgo adicional y una exposición a las pérdidas. Antes de decidirse a operar con divisas, considere cuidadosamente sus objetivos de inversión, su nivel de experiencia y su tolerancia al riesgo. Podría perder una parte o la totalidad de su inversión inicial. No invierta dinero que no puede permitirse perder. Infórmese sobre los riesgos asociados al trading de divisas y pida consejo a un asesor financiero o fiscal independiente si tiene alguna duda. Todos los datos y la información se proporcionan "tal cual" con fines informativos únicamente y no están destinados a fines comerciales o de recomendación. Los resultados pasados no son indicativos de los resultados futuros.